A lack of consensus and few data support testosterone replacement therapy (TRT) in hypogonadal men who have been treated for prostate cancer (CaP), particularly those who have received radiation therapy. We performed retrospective review of 13 hypogonadal men with CaP, treated with brachytherapy or external beam radiotherapy who were subsequently treated with testosterone ( 1 Though men over the age of 65 years currently account for 5.6% of the US population, this age group is growing 2-3 times faster than men o65 years old, suggesting that the prevalence of LOH will only continue to increase.
INTRODUCTION
Late-onset hypogonadism (LOH) is present in up to 7% of men o70 years old and in up to 18.4% of men 470 years old. 1 Though men over the age of 65 years currently account for 5.6% of the US population, this age group is growing 2-3 times faster than men o65 years old, suggesting that the prevalence of LOH will only continue to increase. 2 Characterized by low serum testosterone (T), as well as symptoms of androgen deficiency, which include loss of libido, erectile dysfunction, depression, lethargy, concentration difficulties, sleep disturbance, osteoporosis and loss of muscle strength, LOH has widespread implications on men's health and has been associated with cardiovascular disease, insulin resistance, type II diabetes and metabolic syndrome. [3] [4] [5] [6] Treatment with testosterone replacement therapy (TRT) ameliorates the symptoms of hypogonadism, but is controversial in the setting of prostate cancer (CaP) due to the belief that T can stimulate its growth. A study by Huggins and Hudges 7 in 1941 demonstrated CaP regression in men with metastatic disease after surgical castration and subsequent in vitro studies showed CaP cell growth after treatment with T, further supporting the CaP-androgen relationship. 8 Despite these early findings, there remains a dearth of clinical evidence supporting a link between high serum T and increased CaP risk. Thus, in the light of mounting evidence suggesting worse health outcomes in men diagnosed with hypogonadism, together with the lack of data supporting a clinical association between T and CaP growth, TRT has been initiated in hypogonadal men with CaP.
Most studies examining hypogonadal men receiving TRT after radical prostatectomy (RP) have described no cases of biochemical recurrence or evidence of CaP progression in the setting of localized disease. [9] [10] [11] Similarly, studies of patients with CaP treated with brachytherapy and/or external beam radiotherapy (EBRT) and on TRT have reported transient rises in prostate-specific antigen (PSA), but no patients with CaP recurrence or progression prompting TRT cessation. [12] [13] [14] Furthermore, no evidence of bone metastasis or local recurrence has been observed in hypogonadal patients with locally advanced CaP who underwent surgical castration followed by intermittent TRT, nor have there been significant rises in PSA or evidence of CaP progression in patients with CaP on active surveillance treated with TRT. 15, 16 In one study examining 96 men on TRT after RP, radiation therapy, or intermittent androgen deprivation, with 8 men demonstrating evidence of distant metastasis prior to TRT initiation, TRT was stopped in 60% of men due to rising PSA. 17 The above small studies overall support the use of TRT in patients with CaP, irrespective of CaP treatment modality, in the setting of vigilant follow-up, as does a recent review of the published literature, particularly given the known effects of exogenous T on prostate cell growth in vitro. 18 However, no published data from randomized controlled trials studying outcomes of TRT in treated CaP patients are currently available, and the data from retrospective studies are limited. In this retrospective study, we assess the efficacy and safety of TRT in a cohort of men with CaP treated with radiation, with the goal of adding to the literature describing TRT in men with CaP.
MATERIALS AND METHODS
A retrospective review of all hypogonadal men with a history of CaP treated with either brachytherapy or EBRT (collectively referred to as 'radiation treatment') who subsequently received TRT at Baylor College of Medicine was performed after Institutional Review Board approval; 17 men were identified, 4 of whom were excluded owing to lack of available prostate biopsy data or baseline PSA values. All men underwent radiation treatment for CaP between 1994 and 2009 and TRT was initiated between 2006 and 2010. The diagnosis of hypogonadism was based on the presence of symptoms, including low libido, erectile dysfunction, low energy, poor concentration, inadvertent weight gain and sleep disturbances, as well as serum T p300 ng dl
. Initial TRT consisted of a transdermal T formulation in 12 patients and subcutaneous T pellets in 1 patient. Four patients were placed on androgen deprivation therapy (ADT) prior to starting radiation treatment, one of whom was diagnosed with high-grade disease. Men were also risk-stratified using the National Comprehensive Cancer Network (NCCN) guidelines and 4, 7 and 2 patients were found to be at very low or low, intermediate, or high risk for CaP recurrence, respectively. 19 Baseline serum T, free T (FT), hemoglobin (Hgb), hematocrit (Hct), estrogen (E), sex hormone-binding globulin (SHBG) and PSA levels were determined after completion of EBRT or placement of brachytherapy seeds, but before initiation of TRT. Subsequent hormonal evaluation was performed approximately every 3 months after TRT initiation. PSA velocity (PSAV) was calculated using linear regression of three or more serum PSA values obtained over at least a 12-month period. Of note, PSAV was not determined for one patient, as only two PSA values were available and these were within 5 months of each other. The majority of serum hormone evaluations were performed by the Laboratory for Male Reproductive Research and Testing at Baylor College of Medicine on a single Beckman Coulter Access2 assay system (Beckman Coulter, Brea, CA, USA), with a minority of samples analyzed by outside laboratories. Subjective improvement in libido, erections and energy was assessed using direct questioning of patients prior to initiation of TRT and during follow-up.
Data were analyzed using Microsoft Office Excel (Microsoft, Redmond, WA, USA) and SPSS (IBM Corporation, Somers, NY, USA). Statistical comparisons between baseline and follow-up values were performed using the Wilcoxon rank-sum test, with a P-valuep0.05 considered statistically significant.
RESULTS
Thirteen hypogonadal patients with a history of CaP were treated with TRT after completion of radiation treatment ( Table 1 ). The median time to initiation of TRT after radiation treatment was 13.5 months, and the time from initiation of radiation treatment to last follow-up PSA was 45.6 months. The median age at TRT initiation was 68.0 years. Prostate biopsy results evidenced four patients with Gleason (Gl) 6, 7 with Gl 7 and 2 with Gl 8 disease, with no men having evidence of locally advanced CaP. Using the NCCN guidelines to risk stratify our cohort, we found 4, 7 and 2 patients to be at very low or low, intermediate, or high risk for CaP recurrence, respectively. Of the 13 patients in the cohort, 3 were treated with brachytherapy and 10 with EBRT. Four patients received ADT in addition to radiation treatment for PSA levels of 1.9, 14, 15 and 18 ng ml
respectively. Three patients were started on TRT prior to being diagnosed with CaP and TRT was restarted after CaP treatment.
The median follow-up period after TRT initiation was 29.7 months (range 2. . Median serum T was significantly higher after TRT initiation compared with baseline throughout the duration of follow-up, except for the time periods of 18-24 and 430 months ( Table 2) . No significant increases from baseline FT or E were observed during follow-up. There was an overall increase in the mean SHBG during the course of treatment with significance reached at 18-24 months follow-up (38.5 (34.3- 
Median PSA in the cohort was 0.30 (42.8-49.0) ng ml À 1 at baseline and 0.66 (0.16-1.35) ng ml À 1 at median follow-up (P ¼ 0.345). No significant changes in PSA were observed during the follow-up period of up to 67.3 months ( Table 2 ). The median difference between baseline and PSA at median follow-up was 0.055 ng ml À 1 and the median PSAV within the cohort was À 0.004 ( À 0.080 to 0.010) ng ml À 1 per year. Biochemical recurrence was suspected in one patient with Gl 4 þ 4 ¼ 8 disease who had been treated with brachytherapy as well as ADT. This patient had a preradiation treatment PSA of 18 ng ml À 1 , a pre-TRT PSA of 0.009 ng ml
, with a nadir of 0.002 ng ml À 1 after starting TRT, which subsequently rose to 1.82 ng ml À 1 with a PSAV of 0.93 ng ml
per year, prompting cessation of TRT and workup for CaP recurrence. Repeat prostate biopsy, computed tomography and bone scans showed no evidence of cancer, at which point the patient resumed TRT. His PSA has since remained stable at 1.31 ng ml
on TRT. The second patient who received ADT in addition to radiation treatment had a pre-radiation treatment PSA of 15 ng ml À 1 , a baseline PSA of 0.4 ng ml À 1 prior to TRT initiation, and a maximum PSA of 1.29 ng ml À 1 while on TRT, which subsequently decreased to 0.629 ng ml À 1 during treatment. TRT was not stopped at any point during this patient's follow-up. The third patient who received ADT had a pre-radiation treatment PSA of 14 ng ml À 1 while on TRT, a maximum PSA of 0.30 ng ml À 1 while on TRT, with stable PSA and no evidence of recurrence. Finally, the fourth patient who received ADT had a pre-radiation treatment PSA of 1.9 ng ml À 1 , a baseline PSA of 0.09 ng ml À 1 prior to TRT initiation, a maximum PSA of 0.1 ng ml À 1 during treatment, with transient cessation of TRT due to supraphysiological T levels.
A side effect of exogenous T administration is the development of erythrocytosis. In our cohort, only three patients had baseline Hgb and Hct values available and, as a result, we were unable to make direct comparisons between baseline and follow-up Hgb and Hct. However, the maximum Hgb and Hct in any single patient during follow-up were 17.9 g dl À 1 and 52.3%, respectively, and no men required phlebotomy for erythrocytosis treatment.
Improvement in hypogonadal symptoms was assessed through direct patient questioning and subjective improvements in energy, libido and erections were each reported by 85%, 85% and 54% of men, respectively.
DISCUSSION
The use of TRT in the setting of CaP remains controversial, in large part owing to the androgen responsiveness of CaP and the concern that TRT will stimulate the growth of latent CaP cells. However, mounting evidence supports the safety of TRT in the setting of CaP, though data from randomized controlled trials are currently not available to corroborate these findings. This study assesses the effects of TRT in hypogonadal men having undergone radiation treatment for CaP, and our results suggest that the use of TRT in men with a history of CaP does not increase the risk of CaP recurrence or progression for up to 5.5 years after TRT initiation. These results are consistent with the three prior uncontrolled studies assessing the effects of TRT in a total of 43 men after radiation therapy, [12] [13] [14] as well as the three prior studies of TRT in a total of 74 men after RP. [9] [10] [11] RP and radiation therapy, even in the absence of ADT, have been associated with changes in serum T levels over time, though the underlying mechanism is unknown. One study found that men treated with radiation therapy were more likely to become hypogonadal than men who underwent RP, with a 27.3% lower T and 31.6% lower FT in the radiation therapy group. 20 Two additional studies reported T levels that did not recover to pretreatment levels in 40% of men after EBRT, with median decreases in T of 17-19%. 21, 22 The increased risk of hypogonadism in the setting of radiation therapy is linked to radiation scatter during treatment and resulting testicular damage. 23 Other studies have reported no significant changes in serum T levels after radiation therapy, 24, 25 and several studies have reported drops in T levels after radiation therapy, with subsequent normalization to pretreatment levels. 26 In the setting of CaP treated with RP, one study reported increased T levels, though the mechanism behind this rise is unclear, 27 and other studies have reported no changes in serum T levels after prostatectomy or prostatic adenoma resection. 28, 29 Given the variable effects of CaP treatment on serum T levels, particularly the decline seen in most studies of men treated with radiation, evaluation for hypogonadism in this cohort is clearly important.
All 13 men in our cohort received at least 2 months of TRT, with a median follow-up of 2.5 years after TRT initiation and a maximum follow-up of approximately 5.5 years. It is important to note that several patients were treated with subcutaneous T pellets at some point during therapy and hormone levels were at times drawn several months after pellet insertion towards the end of the efficacy period. 30 Thus, peak serum T levels may have been missed in several patients at several time points. Nevertheless, we observed a significant increase in mean T levels during follow-up. Furthermore, we observed a significant rise in SHBG levels in our cohort, but only at 18-24 months of TRT. While this may be consistent with an increase in serum T, it may also be a statistical artifact considering the time period required for a significant increase. Notably, no significant change in serum E levels was observed, suggesting a low rate of T aromatization within our cohort.
While on TRT, no men in our cohort were found to have recurrence or progression of their cancer. In contrast, the rate of biochemical and/or clinical recurrence in the setting of CaP treated with radiation therapy without TRT is 13-53% and varies according to the definition of recurrence used. [31] [32] [33] [34] Although one patient in our cohort had a suspected biochemical recurrence, subsequent workup demonstrated no evidence of disease.
Notably, this same patient had a baseline T of 40 ng dl À 1 after ADT. This patient's baseline PSA was 0.009 ng ml À 1 and rose to a high of 1.82 ng ml À 1 during TRT, prompting evaluation for CaP recurrence. However, the observed rise in this patient's PSA in the setting of an abnormally low T is consistent with the Prostate Saturation Theory, which posits that prostatic androgen receptors may saturate at a serum T level in the castrate range, and that serum PSA is more likely to rise in the setting of lower serum T levels. 35 Thus, the above patient's prostatic androgen receptors may not have been saturated at the time of TRT initiation in the setting of castrate T levels, resulting in an initial rise in PSA. However, once the patient was eugonadal and his prostate androgen receptors were saturated, there was no further increase in his PSA.
Though numerous definitions of biochemical recurrence exist for men with CaP treated with radiation therapy, the three with the highest sensitivities and specificities after EBRT are: (1) PSA greater than absolute nadir plus 2 ng ml À 1 ; (2) PSA greater than current nadir plus 3 ng ml À 1 ; and (3) two consecutive PSA increases of 40.5 ng ml À 1 . 36 Even though the absolute nadirs for most men in our cohort were unavailable, the maximum PSA after TRT initiation for men treated with EBRT was 1.75 ng ml À 1 and no patients experienced two consecutive increases of 40.5 ng ml À 1 , precluding biochemical recurrences according to the above definitions and further supporting the safe use of TRT in this cohort of men.
Four patients received ADT in addition to radiation therapy, the combination of which has been shown to improve overall survival compared with radiation therapy alone. 37 Given the intermediateto high-risk nature of cancer in these four men, and in the absence of confirmed biochemical recurrences, our data support the efficacious use of TRT without overt clinical consequences, even in men with more serious CaP with continued close follow-up.
One of the most common side effects of TRT is erythrocytosis, which may be caused by suppression of hepcidin by exogenous T. 38 Though rates of erythrocytosis vary depending on the T formulation, transdermal formulations have an approximately 18% rate of associated erythrocytosis 39 and injectable formulations up to 40%. Data are less readily available for rates of erythrocytosis after treatment with subcutaneous T pellets, although a recent prospective study of 30 subjects treated with T pellets resulted in no significant increases in Hct over 6 months. 40 Our results overall corroborate the published findings, as no patients developed erythrocytosis over the course of 5.5 years of follow-up. We acknowledge that the small size of our cohort, as well as limited data, preclude a true assessment of the effects of TRT on Hgb and Hct parameters.
Our study is limited by several factors. First, as indicated above, our study was small, comprising only 13 men, and without a control group. Thus, while several individuals were found to have rising PSA without recurrence of their CaP, extrapolation to a population level based on such a small cohort is not possible. Second, the retrospective nature of the study resulted in limited data, specifically with respect to baseline Hgb and Hct values as well as T levels for men treated with T pellets. Third, the median follow-up of 2.5 years after TRT initiation may be of insufficient duration to detect biochemical recurrence, as recurrences can occur much longer than 2 years after therapy. 41 Finally, assessment of symptomatic improvement on TRT was limited, as symptoms were not assessed using a validated questionnaire, though the recent incorporation of a set of validated online questionnaires in our clinic will remedy this in future work.
In summary, our results are consistent with published data on CaP patients who receive TRT after RP, radiation therapy and while on active surveillance. This study also adds to the body of evidence challenging the androgen-dependent model of CaP growth while supporting the Prostate Saturation Theory, and ultimately supporting the use of TRT to treat hypogonadism despite a diagnosis of CaP. Furthermore, our data demonstrate a lower rate of CaP recurrence in men on TRT than the published recurrence rate for men with CaP not treated with TRT. However, in the continued absence of randomized controlled trial data, TRT in patients with CaP should be undertaken with appropriate follow-up.
